# US 2013/0252836 A1 · Diagnostic test for cardiomyopathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252836 A1
- Document ID: US20130252836A1
- Status: Published application
- Kind: A1
- Application number: 13/827,705
- Filed: 2013-03-14
- Published: 2013-09-26
- Earliest claimed: 2007-12-21
- Assignees: Genesis Group Inc.
- Applicants: Genesis Group Inc.
- Inventors: Terry-Lynn Young; Kathy Hodgkinson; Sean Connors; Patrick Parfrey; Annika Haywood; Nancy Merner; Vanessa French
- Web page: https://patentgrep.com/patent/US20130252836A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/172: Haplotypes
- G01N 2800/325: Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
- G01N 2800/326: Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods and compositions relating to diagnosing and treating cardiomyopathy and particularly relating to methods and compositions for diagnosing and treating arrhythmogenic right ventricular dysplasia/cardiomyophathy (ARVD/C) are described. Provided are methods for screening for, diagnosing or detecting a risk of developing arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) comprising detecting the presence of a transmembrane protein 43 (TMEM43) disease associated variant in a sample of a subject, wherein the presence of a TMEM43 disease variant is indicative that the subject has ARVD/C or an increased risk of developing ARVD/C compared to an individual having wild type TMEM43.

## Claims

### Claim 1

A method of screening for, diagnosing and/or detecting an increased risk of developing arrhythmogenic right ventricular dysplasia/ cardiomyopathy (ARVD/C) in a subject, comprising determining the presence of one or more ARVD/C mutations in TMEM43 in a sample obtained from the subject, and identifying the subject as having ARVD/C or an increased risk of developing ARVD/C.

### Claim 2

A method of identifying a substance which binds mutant TMEM43 comprising one or more ARVD/C mutations comprising:
a. contacting the mutant TMEM43 with a test substance, under conditions which allow for formation of a complex between the mutant TMEM43 and the test substance, and
b. detecting complexes between mutant TMEM43 and the test substance;
wherein the presence of complexes indicates that the test substance binds the mutant TMEM43.

### Claim 3 (depends on 2)

The method of claim 2, wherein the mutant TMEM43 is a polypeptide and the test substance-protein complexes, free test substance or non-complexed mutant TMEM43 polypeptides are isolated by one or more of salting out, chromatography, electrophoresis, gel filtration, fractionation, absorption, polyacrylamide gel electrophoresis, agglutination, or combinations thereof.

### Claim 4

A composition comprising a mutant TMEM43 polypeptide comprising one or more ARVD/C mutations, an antibody specific for a mutant TMEM43 comprising one or more ARVD/C mutations or at least one isolated nucleic acid, wherein the at least one isolated nucleic acid hybridizes to:
a. a RNA product of mutant TMEM43 comprising one or more ARVD/C mutations; and/or
b. a nucleic acid complementary to a); and/or
c. a nucleic acid corresponding to a);
wherein the composition is used to detect a mutant TMEM43 comprising one or more ARVD mutations.

### Claim 5 (depends on 1)

A microarray for use in the method of claim 1 comprising a plurality of probes fixed to a solid surface, wherein at least one of the plurality of probes specifically hybridizes to an ARVD/C associated TMEM43 mutation.

### Claim 6 (depends on 4)

A kit comprising:
a. a mutant TMEM43 detection agent or reagent;
b. a composition of claim 4;
c. a microarray comprising a plurality of probes fixed to a solid surface, wherein at least one of the plurality of probes specifically hybridizes to an ARVD/C associated TMEM43 mutation and/or
d. instructions of use.

### Claim 7 (depends on 6)

The kit of claim 6 wherein the detection agent or reagent comprises an isolated nucleic acid, a probe, one or more primers, optionally a genotyping primer and/or an antibody.

### Claim 8 (depends on 7)

The kit of claim 7, wherein the nucleic acid, probe, primer or antibody is labelled with a detectable label.

### Claim 9 (depends on 8)

The kit of claim 8, wherein the detectable label comprises a fluorescent, radio-opaque, radioisotope, or chemiluminescent (chromophore) compound, an enzyme, an imaging agent or a metal ion.

### Claim 9 (depends on 7)

The kit of claim 7 wherein the nucleic acid or probe comprises 16-20 nucleotides of SEQ ID NO:53.

### Claim 10 (depends on 7)

The kit of claim 7 wherein each of the one or more primers comprises a sequence selected from all or part of SEQ ID NO: 15-52.

### Claim 11 (depends on 7)

The kit of claim 7 wherein the one or more primers is for amplifying an exon, exon/intron boundary and/or intronic TMEM43 sequence.

### Claim 12 (depends on 11)

The kit of claim 11, wherein the one or more primers are for amplifying all or part of exon 12.

### Claim 13 (depends on 12)

The kit of claim 12 wherein the one or more primer are selected from the group comprising SEQ ID NOs: 19, 20, 23, 24, 43-44.

### Claim 14 (depends on 6)

The kit of claim 6, further comprising a nucleic acid or probe for wildtype TMEM43, optionally SEQ ID NO:54.

### Claim 15 (depends on 6)

The kit of claim 6, wherein the kit is a medical diagnostic kit or a laboratory use kit.

### Claim 16 (depends on 6)

The kit of claim 6, wherein the kit comprises one or more reagents for PCR, RT-PCR, NASBA and/or microarray.

### Claim 17 (depends on 16)

The kit of claim 16, wherein the kit comprises one or more of PCR buffer, dNTPs, betaine and polymerase.

### Claim 18 (depends on 6)

The kit of claim 6, wherein the detection agent or reagent comprises a carrier optionally selected from agarose, cellulose, dextran, Sephadex, Sepharose, carboxymethyl cellulose polystyrene, filter paper, ion-exchange resin, plastic film, plastic tube, glass beads, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon and silk.

### Claim 19 (depends on 6)

The kit of claim 6 wherein the one or more mutations comprises a mutation at nucleotide corresponding to 171 of SEQ ID NO:1.

### Claim 20 (depends on 1)

The method of claim 1 wherein the one or more mutations comprises a mutation at nucleotide corresponding to 171 of SEQ ID NO:1.
